Erste Phase-I-Untersuchung von Echinacea-Polysaccharid (EPO Vlla/EPS)bei i.v. Applikation*)

Author(s): Worku, F., Linde, K., Flesche, C., Eife, R., Wagner, H.

Abstract: Objectives: To assess the immunostimulating effects, the compatibility and to find out the optimal dose and time of administration of an i.v. application of a polysaccharide fraction (EPO VIIa) isolated from tissue cultures of Echinacea purpurea.Design: 6 randomized, double-blind, placebo-controlled trials, partially crossover.Subjects: 32 healthy, male volunteers between 21 and 37 years.Main outcome measures: Leucocytes (total and differentiated), phagocytosis of polymorphonuclear neutrophile granulocytes, TNF-alpha, interferon-alpha, activity of NK-cells and lymphocyte subpopulations.Results: Injections of 1 mg and 5 mg EPO Vlla caused an increase of the number of leucocytes (90-150% and 50-90% respectively) segmented granulocytes and TNF-alpha (from < 15 pg/ml to < 15-32 pg/ml and 32-115 pg/ml respectively). In two volunteers 5 mg caused short-time influenza-like symptoms and limb pain.Conclusion: 1 mg EPO VIIA caused a distinct increase of unspecific immunoparameters. The relevance for therapeutics should be tested in clinical studies.

Keyword(s): Echinacca-Polysaccharid

Zurück | Weiter